Tian Medical

Executive Summary

Tian Medical is a San Francisco-based medical device company founded in 2018, specializing in innovative drug delivery systems. Its flagship product, the Tx360® Nasal Applicator, is designed to deliver medication precisely to the sphenopalatine ganglion (SPG) nerves, offering a minimally invasive, targeted treatment option for pain and headache disorders. By enabling direct administration to this key neural hub, the Tx360 aims to improve therapeutic efficacy and reduce systemic side effects compared to conventional oral or injectable therapies. The company's mission is to provide clinicians with a novel tool to address unmet needs in managing chronic pain conditions such as migraine and cluster headaches. Despite being private and early-stage with no disclosed funding or revenue, Tian Medical's focal technology represents a promising advancement in targeted drug delivery. The SPG block has been used clinically for headache management, but the Tx360's precise applicator could standardize and simplify the procedure. The company may benefit from growing interest in non-opioid pain treatments and the expanding market for neuromodulation and localized therapies. Key risks include regulatory hurdles, competition from established nasal sprays and nerve blocks, and the need for robust clinical data. If successful, Tian Medical could capture a niche in the headache treatment landscape. Conviction is moderate given the lack of public financials and commercial traction.

Upcoming Catalysts (preview)

• Q4 2026Publication of Phase II clinical trial results for Tx360 in migraine treatment60% success
• Q2 2027FDA 510(k) clearance or de novo classification for Tx360 in cluster headache50% success
• Q3 2026Strategic partnership or licensing deal with a major pharmaceutical or medical device company30% success